De-escalation in HER2+ Tumors: What Can Imaging Tell Us?
Paula Borralho
HER2-Targeted Therapies: Beyond Trastuzumab
Hassan GHAZAL
What strategy to use to manage side effects in practice?
Georgia DEMETRIOU
oncologist, Johannesburg, SA
Innovations dans le cancer du sein métastatique
Frédérique PENAULT LLORCA
Anatomopathologiste, Clermont Ferrand, France
What are the opportunities brought by the BCU and what are the contributions of genetics to the management of breast cancer?
Pascal PUJOL
Chairman of the Genetic department, University Hospital, Montpellier, France